Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Bod Australia Ltd ( (AU:BOD) ) has provided an announcement.
Bod Science Limited, currently under a Deed of Company Arrangement, reported financial activities for the quarter ending December 2024. The company saw a net cash inflow of $51k from operating activities, with customer receipts amounting to $219k. The sale of certain intellectual property assets generated proceeds of $125k. A significant development includes the execution of a binding Share Purchase Agreement with Biortica’s shareholders, contingent upon shareholder approvals and compliance with ASX requirements. The extraordinary general meeting initially scheduled for November 2024 has been postponed to early-to-mid March 2025 due to delays in Biortica’s financial audit. The company’s operations remain supported under the DOCA, with Biortica funding ongoing trading costs.
More about Bod Australia Ltd
Bod Science Limited is a cannabis-focused drug development and product innovation company. It aims to progress research and development with a clear clinical trial pathway to commercialize premium, scientifically proven products for both patients and consumers. The company has established partnerships with large corporate entities and collaborations with leading research organizations to advance the use of cannabis-related medicines for therapeutic purposes.
YTD Price Performance: 20.0%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$4.26M
See more insights into BOD stock on TipRanks’ Stock Analysis page.